CYBN.NE

Cybin Inc.

Cybin to Announce Second Quarter FY2021 Financial Results and Business Update on November 15, 2021

TORONTO, November 09, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM" today announced that it will report financial results for its second quarter of fiscal 2021 ended September 30, 2021 on Monday, November 15,... Read More...

Calendar488 views8 min read

Cybin Hosting Research and Development Briefing on November 8, 2021

Cybin

Breakthrough pre-clinical, research findings to be released show therapeutic advancements on the data-driven evolution of psychedelic psilocybin moleculeTORONTO, November 02, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to The... Read More...

75 views7 min read

Cybin Announces Launch of EMBARK Psychedelic Facilitator Training Program

Cybin

TORONTO, October 28, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced the launch of the EMBARK Psychedelic Facilitator Training Program.Led by a team of esteemed faculty, the program offers psychedelic clin... Read More...

46 views5 min read

Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies

Cybin

--The Company expects to hold a Research & Development event to review these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media--TORONTO, October 19, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on progr... Read More...

1426 views11 min read

Cybin Announces Election of Theresa Firestone as Director, Results of Shareholders’ Meeting and Adoption of Shareholder Rights Plan

Cybin

TORONTO, August 16, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Theresa Firestone has been elected to its board of directors at the Company’s annual and special meeting of shareholders held... Read More...

92 views4 min read

Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Common Shares

Cybin

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, July 28, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, announced today the pricing of its previously announced overnight market... Read More...

70 views4 min read

Cybin Receives Final Approval to Commence Trading on the NYSE American on or About August 5

Cybin

TORONTO, July 28, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has received approval for the listing of its common shares on the NYSE American LLC stock exchange ("NYSE American"). The Company expects ... Read More...

Financials96 views7 min read

Cybin Inc. Releases Annual Financials and Provides Business Highlights

Cybin

TORONTO, June 28, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today released financial and business highlights for its financial year ended March 31, 2021. Unless otherwise indicated, all amounts in this press release are in... Read More...

67 views4 min read

Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study

Cybin

TORONTO, Jun 22, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced the completion of its 51st pre-clinical study as it continues to progress its proprietary psychedelic molecules into Investigational New Drug ("IND... Read More...

Joint Venture104 views6 min read

Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic Therapeutics

Cybin

HIGHLIGHTSUsing Kernel’s technology, Cybin will be able to quantify brain activity in real time during psychedelic experiences. The absence of this data has been a limitation in the progression of new molecules targeting neurological disorders.Kernel’s technology opens new frontier in psychedelic therapeutics by acquiring longitudinal bra... Read More...

Financials982 views2 min read

Cybin Announces First Quarter Financial Results of Clarmin Explorations Inc.

Cybin

Cybin Inc. (NEO:CYBN) ("Cybin"), a life sciences company focused on psychedelic pharmaceutical therapies, announces the unaudited financial results of Clarmin Explorations Inc. (now Cybin Inc.) for the three month period ended October 31, 2020. A copy of the unaudited consolidated financial statements prepared in accordance with Internati... Read More...

M & A365 views12 min read

CYBIN Signs Definitive Agreement to Acquire Adelia Therapeutics as Part of its Commitment to Strategic Growth

Cybin

Cybin to host conference call today, December 7, 2020, at 5:00 p.m. ETTransaction adds extensive intellectual property portfolio and product pipeline to potentially diversify Cybin’s programs and includes multiple additional indications.Adelia brings a range of technologies related to novel therapeutics, delivery methods, and therapeutic ... Read More...

CYBN.NE

Make smarter investment strategies with in-depth news reports

Make smarter investment strategies
with in-depth news reports